EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Meningioma methylation profiling as a complement to WHO grading: a single-center experience

Lydia Karamani, Wolf Müller, Max Braune, Peter Baumgarten, Christian Senft

Neurosurgical Focus · 01.09.2026 · 61 (3) · E12

DOI: 10.3171/2026.6.focus26238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, erschienen am 01.09.2026. Verfasst von Lydia Karamani und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Jena University Hospital, Friedrich-Schiller-University, Jena; and. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, DNA Methylation. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE The methylation profile of meningiomas is a promising predictive tool that may improve risk stratification beyond WHO grading. This study aimed to evaluate the clinical relevance and real-world applicability of routine epigenetic testing in meningioma management. METHODS The authors retrospectively analyzed patients who underwent meningioma resection between January 2021 and December 2023. Histopathological grading (WHO 2021) and methylation profiling (methylation class [MC]) with the MethylationEPIC v1.0 (850k) chip were performed by an independent neuropathologist. RESULTS A total of 106 patients were included; 81 tumors (76%) were classified as WHO grade 1, 20 (19%) as grade 2, and 5 (5%) as grade 3. Epigenetically, 55 tumors (52%) were classified as benign, 18 (17%) as intermediate, and 2 (2%) as malignant; 31 (29%) could not be classified. Discordances between WHO grading and methylation profiling were observed in 18 of 74 cases. Tumor board decisions were made after a median of 8 days postoperatively, guided by WHO grading; however, the epigenetic report was only available after a median of 23 days. During follow-up, 20 patients experienced tumor progression. Progression was significantly associated with the MC (r = −0.4, p < 0.001) and tumor volume (r = 0.4, p = 0.0005), but not with WHO grading (r = 0.17, p = 0.084). However, the relatively high rate of unclassified tumors and delayed result availability limited the direct impact of MC profiling on immediate clinical decision-making. Interestingly, progression-free survival in MC-unclassified tumors mirrored that of the intermediate group. CONCLUSIONS Methylation profiling demonstrates superior predictive accuracy for meningioma progression and complements WHO grading, especially in identifying malignant meningiomas. However, its current clinical utility is constrained by technical and logistical limitations. In real-world practice, epigenetic classification should therefore be considered a complementary tool rather than a replacement for established histopathological assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsDNA MethylationHumansFemaleNeoplasm GradingRetrospective StudiesMaleMiddle AgedWorld Health OrganizationAgedAdult

Stichwörter der Autor:innen

MC classifiermeningiomamethylation classmethylation profile

Autor:innen und Institutionen

  • 1Department of Neurosurgery, Jena University Hospital, Friedrich-Schiller-University, Jena; and.
  • 2Paul Flechsig Institute of Neuropathology, Leipzig University Hospital, Leipzig, Germany.

Zitieren

APA

Karamani, L., Müller, W., Braune, M., Baumgarten, P., & Senft, C. (2026). Meningioma methylation profiling as a complement to WHO grading: a single-center experience. Neurosurgical Focus, 61(3), E12. https://doi.org/10.3171/2026.6.focus26238

Vancouver

Karamani L, Müller W, Braune M, Baumgarten P, Senft C. Meningioma methylation profiling as a complement to WHO grading: a single-center experience. Neurosurgical Focus. 2026;61(3):E12. doi:10.3171/2026.6.focus26238

BibTeX
@article{Karamani2026,
  author = {Karamani, Lydia and Müller, Wolf and Braune, Max and Baumgarten, Peter and Senft, Christian},
  title = {Meningioma methylation profiling as a complement to WHO grading: a single-center experience},
  journal = {Neurosurgical Focus},
  year = {2026},
  volume = {61},
  number = {3},
  pages = {E12},
  doi = {10.3171/2026.6.focus26238}
}
Kostenlos starten →